These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24522402)

  • 21. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.
    Chu QS; Sangha R; Hotte SJ; Sergenson G; Schnell D; Chand VK; Hirte HW
    Invest New Drugs; 2014 Dec; 32(6):1226-35. PubMed ID: 25037863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.
    Bonate PL; Floret S; Bentzen C
    Br J Clin Pharmacol; 2004 Aug; 58(2):142-55. PubMed ID: 15255796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dermatologic adverse events associated with afatinib: an oral ErbB family blocker.
    Lacouture ME; Schadendorf D; Chu CY; Uttenreuther-Fischer M; Stammberger U; O'Brien D; Hauschild A
    Expert Rev Anticancer Ther; 2013 Jun; 13(6):721-8. PubMed ID: 23506519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
    Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL
    J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin
    Quartino AL; Li H; Kirschbrown WP; Mangat R; Wada DR; Garg A; Jin JY; Lum B
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):329-340. PubMed ID: 30467591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.
    Yang JC; Shih JY; Su WC; Hsia TC; Tsai CM; Ou SH; Yu CJ; Chang GC; Ho CL; Sequist LV; Dudek AZ; Shahidi M; Cong XJ; Lorence RM; Yang PC; Miller VA
    Lancet Oncol; 2012 May; 13(5):539-48. PubMed ID: 22452895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies.
    Dosne AG; Valade E; Stuyckens K; Li LY; Ouellet D; Perez-Ruixo JJ
    J Clin Pharmacol; 2020 Apr; 60(4):515-527. PubMed ID: 31742712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
    Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
    Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer.
    Li J; Al-Huniti N; Henningsson A; Tang W; Masson E
    Br J Clin Pharmacol; 2017 Aug; 83(8):1723-1733. PubMed ID: 28213941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR.
    Sharma S; Mittapalli RK; Holen KD; Xiong H
    Clin Pharmacokinet; 2015 Oct; 54(10):1071-81. PubMed ID: 25761639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors.
    Tjulandin S; Moiseyenko V; Semiglazov V; Manikhas G; Learoyd M; Saunders A; Stuart M; Keilholz U
    Invest New Drugs; 2014 Feb; 32(1):145-53. PubMed ID: 23589215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients.
    Perez-Ruixo JJ; Piotrovskij V; Zhang S; Hayes S; De Porre P; Zannikos P
    Br J Clin Pharmacol; 2006 Jul; 62(1):81-96. PubMed ID: 16842381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.
    Marshall J; Hwang J; Eskens FA; Burger H; Malik S; Uttenreuther-Fischer M; Stopfer P; Ould-Kaci M; Cohen RB; Lewis NL
    Invest New Drugs; 2013 Apr; 31(2):399-408. PubMed ID: 23161335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors.
    Camidge DR; Sequist LV; Jänne PA; Weickhardt AJ; Dowling ES; Alicea J; Fan J; Oxnard GR
    Clin Lung Cancer; 2018 Sep; 19(5):e655-e665. PubMed ID: 29861396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.
    Garg A; Quartino A; Li J; Jin J; Wada DR; Li H; Cortés J; McNally V; Ross G; Visich J; Lum B
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):819-29. PubMed ID: 25119184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
    Murakami H; Tamura T; Takahashi T; Nokihara H; Naito T; Nakamura Y; Nishio K; Seki Y; Sarashina A; Shahidi M; Yamamoto N
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):891-9. PubMed ID: 22071596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.
    Houk BE; Bello CL; Kang D; Amantea M
    Clin Cancer Res; 2009 Apr; 15(7):2497-506. PubMed ID: 19258444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
    Landi L; Tiseo M; Chiari R; Ricciardi S; Rossi E; Galetta D; Novello S; Milella M; D'Incecco A; Minuti G; Tibaldi C; Salvini J; Facchinetti F; Haspinger ER; Cortinovis D; Santo A; Banna G; Catino A; GiajLevra M; Crinò L; de Marinis F; Cappuzzo F
    Clin Lung Cancer; 2014 Nov; 15(6):411-417.e4. PubMed ID: 25242668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
    Wislez M; Malka D; Bennouna J; Mortier L; Bensadoun RJ; Sicard J; Dielenseger P; Rey JB; Moro-Sibilot D; Scotté F
    Bull Cancer; 2014 Jun; 101(6):647-52. PubMed ID: 24977454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.